[Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis].
BACKGROUND
Community-acquired non-complicated acute pyelonephritis (APN) is a frequent, occasionally serious infection (around 20% of the cases are bacteremic) that usually requires hospital admission. The third generation oral cephalosporins which are active against more than 95% of E. coli strains should allow the outpatient management of these patients.


OBJECTIVE
To evaluate the bacteriological and clinical efficacy of oral cefixime in comparison to amoxicilin plus netilcilin in the treatment of APN.


METHODS
Patients older than 18 years affected by APN were included in a fourteen month prospective study. According to a random numbers chart, the patients received cefixime (400 mg/24 h in a single daily dose for 12 days) or amoxicilin (1 g/8 h per os) plus netilmicin (4 mg/kg/24 h in a single intramuscular daily dose) during five days followed by 7 days of an oral treatment chosen according to the susceptibility pattern of isolated microorganism.


RESULTS
Sixty-one patients received cefixime and 65 amoxicillin plus retilmicin. There were no significant differences between both groups of patients. Thirty-two patients presented bacteremia (25.4%). The mean (SD) eak and trough concentrations of netilmicin were 11.4 (2.8) mg/l and 0.38 (0.4) mg/l, respectively. Clinical response was favorable in 97% of patients treated with cefixime and in 98% of those treated with amoxicilin plus netilmicin (p = NS). The infection recurred in 10 out of 59 patients (16.9%) in the cefixime arm of the study and in 9 out of 64 patients (14%) treated with amoxicillin plus netilmicin (p = NS). Tolerance to the study drugs was good in both arms of the study, and renal function remained normal.


CONCLUSIONS
Cefixime seems to be an acceptable alternative to the regimens containing an aminopenicillin and an aminoglycoside for the treatment of community-acquired non-complicated APN.
Moreno-Martínez
A
A
Servicios de Enfermedades Infecciosas y Microbiología, Hospital Clínic i Provincial, Barcelona.
Mensa
J
J
Martínez
J A
JA
Marco
F
F
Vila
J
J
Almela
M
M
García San Miguel
J
J
Soriano
E
E
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000188:drug therapy; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy*
D002511:Cephalosporins; D009428:Netilmicin; D000658:Amoxicillin; D020682:Cefixime; D002439:Cefotaxime
Cefixima frente a la asociación de amoxicilina con netilmicina en el tratamiento de la pielonefritis aguda no complicada.